샘플 요청 목록

 카트 문의
시장보고서
상품코드
1777778

세계의 탄저균 치료 시장

Anthrax Treatment
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 373 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

탄저균 치료 세계 시장은 2030년까지 6억 1,330만 달러에 이를 전망

2024년에 4억 900만 달러로 추정되는 탄저균 치료 세계 시장은 2024-2030년의 분석 기간에 CAGR 7.0%로 성장하여 2030년에는 6억 1,330만 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 항생제 약제 클래스별은 CAGR 7.8%를 나타내고, 분석 기간 종료시에는 3억 8,120만 달러에 이를 것으로 예측됩니다. 면역글로불린 약제 클래스별 부문의 성장률은 분석 기간중 CAGR 6.2%로 추정됩니다.

미국 시장은 1억 1,140만 달러로 추정, 중국은 CAGR 11.1%로 성장 예측

미국의 탄저균 치료 시장은 2024년에 1억 1,140만 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 1억 2,910만 달러 규모에 이를 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 11.1%로 추정됩니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 3.4%와 6.8%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 4.6%를 나타낼 전망입니다.

세계의 탄저균 치료 시장 - 주요 동향과 촉진요인 정리

탄저균 치료가 세계 보건의 우선순위인 이유는 무엇인가?

탄저균(Bacillus anthracis)에 의한 심각한 전염병인 탄저병은 광범위한 발병 가능성과 생물학 무기로서의 사용으로 인해 여전히 공중보건에 심각한 우려를 낳고 있습니다. 이 질병은 주로 가축에 감염되지만, 감염된 동물이나 오염된 축산물에 직접 접촉하면 사람에게도 감염될 수 있습니다. 피부형, 소화기형, 흡입형, 주사형 탄저병의 중증도는 다양하지만 흡입형 탄저병이 가장 치명적입니다. 치사율과 장기적인 건강 합병증을 최소화하기 위해서는 효과적인 치료가 필수적이며, 확실한 의료적 개입의 중요성이 강조되고 있습니다. 생물테러의 위험이 증가함에 따라 탄저균 치료 솔루션의 필요성이 더욱 부각되고 있습니다. 정부와 보건기관은 의료 대응책 개발 및 비축을 포함한 대비책 마련을 위해 적극적으로 투자하고 있습니다. 또한, 조기 발견 및 대응 능력을 향상시키고, 접근하기 쉽고 효과적인 치료법의 필요성을 강조하기 위한 인식 개선 캠페인과 교육 프로그램도 진행하고 있습니다. 이러한 노력은 탄저균이 심각한 위협이라는 점과 그 영향을 완화하는 데 있어 치료가 중요한 역할을 한다는 점을 전 세계적으로 인식시키는 데 기여하고 있습니다.

어떤 발전이 탄저균 치료의 선택을 바꿀 것인가?

항균제, 생물학적 제제, 지지요법 등의 발전으로 탄저균 치료의 상황은 크게 변화하고 있습니다. 시프로플록사신, 독시사이클린, 아목시실린 등의 항생제는 특히 피부형 및 흡입형 질환에 대한 탄저균 치료의 핵심으로 사용되고 있습니다. 그러나 최근 기술 혁신은 사용 가능한 선택의 폭을 넓혀주고 있습니다. raxibacumab과 obiltoxaximab과 같은 단클론 항체는 탄저균 독소를 표적으로 하는 치료제로 등장하여 기존 항생제를 견디지 못하거나 반응하지 않는 환자들에게 대안을 제시하고 있습니다. 또한 탄저병 백신의 개발은 예방과 조기 치료에 매우 중요한 역할을 하고 있습니다. BioThrax(AVA) 백신과 같은 백신은 군인 및 응급 대응 요원을 포함한 위험에 처한 사람들에게 예방접종을 하는 데 필수적입니다. 효능과 안전성을 향상시킨 차세대 백신에 대한 연구는 계속 진행되고 있으며, 탄저균 노출에 대한 예방 효과를 향상시킬 수 있을 것으로 기대되고 있습니다. 또한, 중합효소연쇄반응(PCR) 검사, 신속 항원 검출 시스템 등 진단 기술의 발전으로 조기 진단과 적시 치료가 용이해져 환자의 예후가 개선되고 사망률이 감소하고 있습니다.

지역 동향은 탄저균 치료 시장을 어떻게 형성하고 있는가?

탄저균 치료 수요는 지역마다 다르며, 공중 보건 인프라, 질병 유행, 정부 이니셔티브의 차이에 따라 영향을 받습니다. 북미는 첨단 헬스케어 시스템, 바이오테러 대응에 대한 막대한 투자, 연구개발 활동에 대한 강력한 지원으로 시장을 독점하고 있습니다. 미국 정부의 전략적 국가비축 프로그램은 탄저균 백신, 항생제, 단클론 항체 수요를 촉진하는 데 중요한 역할을 하고 있으며, 생물학적 공격이나 전염병 발생에 대비하고 있습니다. 유럽에서는 인수공통전염병에 대한 인식이 높아지고 공중보건 대책에 대한 투자가 증가하면서 탄저균 치료 솔루션의 채택이 가속화되고 있습니다. 독일, 영국, 프랑스 등 국가에서는 종합적인 질병 감시 시스템을 구축하고 탄저균 발생 가능성에 대처하기 위한 대책을 비축하고 있습니다. 한편, 아시아태평양은 농업 기반이 크고 인수공통전염병이 빈번하게 발생하기 때문에 급성장하고 있습니다. 중국이나 인도와 같은 국가들은 탄저균 대책으로 백신 생산과 헬스케어 인프라에 투자하고 있습니다. 라틴아메리카와 아프리카는 가축의 수가 많고 헬스케어에 대한 접근성이 제한적인 지역이기 때문에 고유한 문제도 있지만, 인지도와 헬스케어에 대한 인식이 개선된다면 시장 확대의 기회도 있을 것입니다.

탄저균 치료 시장의 성장 원동력은?

탄저균 치료 시장의 성장은 생물테러 대응에 대한 정부 투자 증가, 치료 옵션의 발전, 인수공통전염병에 대한 인식 증가 등 여러 요인에 의해 주도되고 있습니다. 가축이 많은 지역에서는 탄저균의 유행이 확대되고 있으며, 발병을 예방하고 치료하기 위한 백신과 항생제에 대한 수요가 증가하고 있습니다. 또한, 단클론 항체 치료의 도입으로 특히 흡입성 탄저병과 같은 심각한 사례에 대한 효과적인 치료법을 제공함으로써 시장 성장을 더욱 촉진하고 있습니다. 질병 감시, 조기 진단 및 대책에 대한 접근성을 개선하기 위한 공중 보건 노력도 시장 확대에 기여하고 있습니다. 특히 고위험군의 예방접종률 격차를 해소하기 위해 안전성 프로파일이 개선되고 투여가 용이한 차세대 백신 개발에 집중하고 있습니다. 특히 아시아태평양과 아프리카에서는 헬스케어 인프라와 연구 활동에 대한 지역적 투자가 시장을 더욱 강화시키고 있습니다. 이러한 요인을 종합하면, 세계 보건 안보에서 탄저균 치료의 중요한 역할과 시장의 강력한 성장 궤도를 강조합니다.

부문

약제 클래스별(항생제 약제 클래스, 면역글로불린 약제 클래스, 기타 약제 클래스), 감염 유형별(피부 감염, 기타 감염 유형), 유통 채널별(병원 약국, 소매 약국, 기타 유통 채널)

조사 대상 기업 예

  • AbVacc, Inc.
  • Acurx Pharmaceuticals
  • BlueWillow Biologics, Inc.
  • Elusys Therapeutics, Inc.
  • Emergent BioSolutions Inc.
  • GC Biopharma Corporation
  • GSK Plc
  • Paratek Pharmaceuticals, Inc.
  • Pfizer, Inc.
  • Planet Biotechnology, Inc.
  • Porton Biopharma Limited
  • Soligenix, Inc.

AI 통합

검증된 전문가 컨텐츠와 AI툴에 의해 시장 정보와 경쟁 정보를 변혁합니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 25.08.06

Global Anthrax Treatment Market to Reach US$613.3 Million by 2030

The global market for Anthrax Treatment estimated at US$409.0 Million in the year 2024, is expected to reach US$613.3 Million by 2030, growing at a CAGR of 7.0% over the analysis period 2024-2030. Antibiotics Drug Class, one of the segments analyzed in the report, is expected to record a 7.8% CAGR and reach US$381.2 Million by the end of the analysis period. Growth in the Immunoglobulins Drug Class segment is estimated at 6.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$111.4 Million While China is Forecast to Grow at 11.1% CAGR

The Anthrax Treatment market in the U.S. is estimated at US$111.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$129.1 Million by the year 2030 trailing a CAGR of 11.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.4% and 6.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.6% CAGR.

Global Anthrax Treatment Market - Key Trends & Drivers Summarized

Why Is Anthrax Treatment a Global Health Priority?

Anthrax, a severe infectious disease caused by the bacterium Bacillus anthracis, remains a critical public health concern due to its potential to cause widespread outbreaks and its use as a biological weapon. The disease primarily affects livestock but can be transmitted to humans through direct contact with infected animals or contaminated animal products. Cutaneous, gastrointestinal, inhalational, and injectional forms of anthrax pose varying degrees of severity, with inhalational anthrax being the most lethal. Effective treatment is essential to minimize fatalities and long-term health complications, underscoring the importance of robust medical interventions. The heightened risk of bioterrorism has further spotlighted the need for anthrax treatment solutions. Governments and health organizations are actively investing in preparedness initiatives, including the development and stockpiling of medical countermeasures. Awareness campaigns and educational programs have also improved early detection and response capabilities, emphasizing the need for accessible and effective treatment options. Together, these efforts reflect the global recognition of anthrax as a significant threat and the critical role of treatment in mitigating its impact.

What Advances Are Transforming Anthrax Treatment Options?

The anthrax treatment landscape has evolved significantly with advancements in antimicrobial therapies, biologics, and supportive care strategies. Antibiotics, such as ciprofloxacin, doxycycline, and amoxicillin, remain the cornerstone of anthrax treatment, particularly for cutaneous and inhalational forms of the disease. Recent innovations, however, have expanded the scope of available options. Monoclonal antibodies like raxibacumab and obiltoxaximab have emerged as life-saving treatments, targeting anthrax toxins and offering an alternative for patients who cannot tolerate or do not respond to conventional antibiotics. Additionally, the development of anthrax vaccines has played a pivotal role in prevention and early intervention. Vaccines such as the BioThrax (AVA) vaccine are critical in immunizing at-risk populations, including military personnel and first responders. Research into next-generation vaccines with improved efficacy and safety profiles continues to advance, promising enhanced protection against anthrax exposure. Furthermore, advancements in diagnostic technologies, such as polymerase chain reaction (PCR) tests and rapid antigen detection systems, have facilitated early diagnosis and timely treatment, improving patient outcomes and reducing mortality rates.

How Are Regional Trends Shaping the Anthrax Treatment Market?

The demand for anthrax treatment varies across regions, influenced by differences in public health infrastructure, disease prevalence, and government initiatives. North America dominates the market, driven by its advanced healthcare systems, significant investments in bioterrorism preparedness, and strong support for research and development activities. The U.S. government’s strategic national stockpile program has played a key role in driving demand for anthrax vaccines, antibiotics, and monoclonal antibodies, ensuring readiness in the event of a biological attack or outbreak. In Europe, growing awareness of zoonotic diseases and increasing investments in public health preparedness are driving the adoption of anthrax treatment solutions. Countries such as Germany, the UK, and France have established comprehensive disease surveillance systems and stockpiled countermeasures to address potential anthrax outbreaks. Meanwhile, the Asia-Pacific region is witnessing rapid growth due to its large agricultural base and frequent zoonotic disease outbreaks. Countries like China and India are investing in vaccine production and healthcare infrastructure to combat anthrax. Latin America and Africa, regions with high livestock populations and limited healthcare access, present unique challenges but also opportunities for market expansion as awareness and healthcare initiatives improve.

What Is Driving Growth in the Anthrax Treatment Market?

The growth in the anthrax treatment market is driven by several factors, including increasing government investments in bioterrorism preparedness, advancements in therapeutic options, and rising awareness of zoonotic diseases. The growing prevalence of anthrax in livestock-rich regions has heightened demand for vaccines and antibiotics to prevent and treat outbreaks. Additionally, the introduction of monoclonal antibody therapies has provided effective treatment alternatives for severe cases, particularly inhalational anthrax, further driving market growth. Public health initiatives to improve disease surveillance, early diagnosis, and access to countermeasures are also contributing to the market’s expansion. The focus on developing next-generation vaccines with improved safety profiles and ease of administration is addressing gaps in immunization coverage, particularly in high-risk populations. Regional investments in healthcare infrastructure and research activities, especially in Asia-Pacific and Africa, are further bolstering the market. Collectively, these factors underscore the critical role of anthrax treatment in global health security and the market’s strong growth trajectory.

SCOPE OF STUDY:

The report analyzes the Anthrax Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Antibiotics Drug Class, Immunoglobulins Drug Class, Other Drug Classes); Infection Type (Cutaneous Infection, Other Infection Types); Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

  • AbVacc, Inc.
  • Acurx Pharmaceuticals
  • BlueWillow Biologics, Inc.
  • Elusys Therapeutics, Inc.
  • Emergent BioSolutions Inc.
  • GC Biopharma Corporation
  • GSK Plc
  • Paratek Pharmaceuticals, Inc.
  • Pfizer, Inc.
  • Planet Biotechnology, Inc.
  • Porton Biopharma Limited
  • Soligenix, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Anthrax Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Threat of Bioterrorism and Biosecurity Concerns Propel Market Demand for Anthrax Treatments
    • Increasing Government Stockpiling of Emergency Antibiotics and Biologics Strengthens Business Case for Anthrax Therapeutics
    • Advancements in Rapid Diagnostic Technologies Spur Early Detection and Timely Treatment of Anthrax Infections
    • Surging Demand for Monoclonal Antibodies and Immunotherapies Strengthens Market Growth for Biologic Anthrax Countermeasures
    • Increasing Awareness and Training on Bioterrorism Preparedness Generates Demand for Anthrax Medical Countermeasures
    • Integration of AI and Big Data in Epidemiology Enhances Surveillance and Response Strategies for Anthrax Outbreaks
    • Global Health Security Initiatives and Pandemic Preparedness Programs Propel Market Investment in Anthrax Treatment Solutions
    • Growing Interest in Novel Small-Molecule Antibiotics Expands Treatment Options for Antibiotic-Resistant Anthrax Strains
    • Expansion of Biopharmaceutical Research Pipelines Spurs Innovation in Targeted Anthrax Therapies
    • Increasing Military and Homeland Security Funding for Biothreat Preparedness Sustains Growth in Anthrax Treatment Research
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Anthrax Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Anthrax Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Anthrax Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Anthrax Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Antibiotics Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Antibiotics Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Antibiotics Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Immunoglobulins Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Immunoglobulins Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Immunoglobulins Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Cutaneous Infection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Cutaneous Infection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Cutaneous Infection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Infection Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Infection Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Infection Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Hospital Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Retail Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Anthrax Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Anthrax Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Anthrax Treatment by Infection Type - Percentage Breakdown of Value Sales for Cutaneous Infection and Other Infection Types for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Anthrax Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Anthrax Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Anthrax Treatment by Infection Type - Percentage Breakdown of Value Sales for Cutaneous Infection and Other Infection Types for the Years 2015, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Anthrax Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • JAPAN
    • Anthrax Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Anthrax Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Anthrax Treatment by Infection Type - Percentage Breakdown of Value Sales for Cutaneous Infection and Other Infection Types for the Years 2015, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Anthrax Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • CHINA
    • Anthrax Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: China 15-Year Perspective for Anthrax Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Anthrax Treatment by Infection Type - Percentage Breakdown of Value Sales for Cutaneous Infection and Other Infection Types for the Years 2015, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for Anthrax Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • EUROPE
    • Anthrax Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Anthrax Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Anthrax Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Europe 15-Year Perspective for Anthrax Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Anthrax Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Anthrax Treatment by Infection Type - Percentage Breakdown of Value Sales for Cutaneous Infection and Other Infection Types for the Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Anthrax Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • FRANCE
    • Anthrax Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 77: France Recent Past, Current & Future Analysis for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: France 15-Year Perspective for Anthrax Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for Anthrax Treatment by Infection Type - Percentage Breakdown of Value Sales for Cutaneous Infection and Other Infection Types for the Years 2015, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for Anthrax Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • GERMANY
    • Anthrax Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany Historic Review for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Germany 15-Year Perspective for Anthrax Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for Anthrax Treatment by Infection Type - Percentage Breakdown of Value Sales for Cutaneous Infection and Other Infection Types for the Years 2015, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for Anthrax Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 95: Italy Recent Past, Current & Future Analysis for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Italy Historic Review for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Italy 15-Year Perspective for Anthrax Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for Anthrax Treatment by Infection Type - Percentage Breakdown of Value Sales for Cutaneous Infection and Other Infection Types for the Years 2015, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for Anthrax Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Anthrax Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 104: UK Recent Past, Current & Future Analysis for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: UK 15-Year Perspective for Anthrax Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 107: UK Recent Past, Current & Future Analysis for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for Anthrax Treatment by Infection Type - Percentage Breakdown of Value Sales for Cutaneous Infection and Other Infection Types for the Years 2015, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for Anthrax Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 113: Spain Recent Past, Current & Future Analysis for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Spain Historic Review for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Spain 15-Year Perspective for Anthrax Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Spain 15-Year Perspective for Anthrax Treatment by Infection Type - Percentage Breakdown of Value Sales for Cutaneous Infection and Other Infection Types for the Years 2015, 2025 & 2030
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Spain 15-Year Perspective for Anthrax Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 122: Russia Recent Past, Current & Future Analysis for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Russia Historic Review for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Russia 15-Year Perspective for Anthrax Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Russia 15-Year Perspective for Anthrax Treatment by Infection Type - Percentage Breakdown of Value Sales for Cutaneous Infection and Other Infection Types for the Years 2015, 2025 & 2030
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Russia 15-Year Perspective for Anthrax Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Europe Historic Review for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Europe 15-Year Perspective for Anthrax Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 15-Year Perspective for Anthrax Treatment by Infection Type - Percentage Breakdown of Value Sales for Cutaneous Infection and Other Infection Types for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 15-Year Perspective for Anthrax Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Anthrax Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Anthrax Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 141: Asia-Pacific Historic Review for Anthrax Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Asia-Pacific 15-Year Perspective for Anthrax Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 15-Year Perspective for Anthrax Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for Anthrax Treatment by Infection Type - Percentage Breakdown of Value Sales for Cutaneous Infection and Other Infection Types for the Years 2015, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for Anthrax Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Anthrax Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 152: Australia Recent Past, Current & Future Analysis for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Australia Historic Review for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Australia 15-Year Perspective for Anthrax Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Australia 15-Year Perspective for Anthrax Treatment by Infection Type - Percentage Breakdown of Value Sales for Cutaneous Infection and Other Infection Types for the Years 2015, 2025 & 2030
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Australia 15-Year Perspective for Anthrax Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • INDIA
    • Anthrax Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 161: India Recent Past, Current & Future Analysis for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: India Historic Review for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: India 15-Year Perspective for Anthrax Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 164: India Recent Past, Current & Future Analysis for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: India 15-Year Perspective for Anthrax Treatment by Infection Type - Percentage Breakdown of Value Sales for Cutaneous Infection and Other Infection Types for the Years 2015, 2025 & 2030
    • TABLE 167: India Recent Past, Current & Future Analysis for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: India 15-Year Perspective for Anthrax Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 170: South Korea Recent Past, Current & Future Analysis for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: South Korea Historic Review for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: South Korea 15-Year Perspective for Anthrax Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: South Korea 15-Year Perspective for Anthrax Treatment by Infection Type - Percentage Breakdown of Value Sales for Cutaneous Infection and Other Infection Types for the Years 2015, 2025 & 2030
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: South Korea 15-Year Perspective for Anthrax Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Asia-Pacific Historic Review for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Rest of Asia-Pacific 15-Year Perspective for Anthrax Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Anthrax Treatment by Infection Type - Percentage Breakdown of Value Sales for Cutaneous Infection and Other Infection Types for the Years 2015, 2025 & 2030
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Anthrax Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Anthrax Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 188: Latin America Recent Past, Current & Future Analysis for Anthrax Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 189: Latin America Historic Review for Anthrax Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Latin America 15-Year Perspective for Anthrax Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: Latin America 15-Year Perspective for Anthrax Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for Anthrax Treatment by Infection Type - Percentage Breakdown of Value Sales for Cutaneous Infection and Other Infection Types for the Years 2015, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for Anthrax Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 200: Argentina Recent Past, Current & Future Analysis for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Argentina Historic Review for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Argentina 15-Year Perspective for Anthrax Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Argentina 15-Year Perspective for Anthrax Treatment by Infection Type - Percentage Breakdown of Value Sales for Cutaneous Infection and Other Infection Types for the Years 2015, 2025 & 2030
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Argentina 15-Year Perspective for Anthrax Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 209: Brazil Recent Past, Current & Future Analysis for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Brazil Historic Review for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: Brazil 15-Year Perspective for Anthrax Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 214: Brazil 15-Year Perspective for Anthrax Treatment by Infection Type - Percentage Breakdown of Value Sales for Cutaneous Infection and Other Infection Types for the Years 2015, 2025 & 2030
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 217: Brazil 15-Year Perspective for Anthrax Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 218: Mexico Recent Past, Current & Future Analysis for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Mexico Historic Review for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 220: Mexico 15-Year Perspective for Anthrax Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 223: Mexico 15-Year Perspective for Anthrax Treatment by Infection Type - Percentage Breakdown of Value Sales for Cutaneous Infection and Other Infection Types for the Years 2015, 2025 & 2030
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 226: Mexico 15-Year Perspective for Anthrax Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Rest of Latin America Historic Review for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 229: Rest of Latin America 15-Year Perspective for Anthrax Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 15-Year Perspective for Anthrax Treatment by Infection Type - Percentage Breakdown of Value Sales for Cutaneous Infection and Other Infection Types for the Years 2015, 2025 & 2030
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 15-Year Perspective for Anthrax Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Anthrax Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 236: Middle East Recent Past, Current & Future Analysis for Anthrax Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 237: Middle East Historic Review for Anthrax Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 238: Middle East 15-Year Perspective for Anthrax Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 241: Middle East 15-Year Perspective for Anthrax Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for Anthrax Treatment by Infection Type - Percentage Breakdown of Value Sales for Cutaneous Infection and Other Infection Types for the Years 2015, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for Anthrax Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 248: Iran Recent Past, Current & Future Analysis for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Iran Historic Review for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 250: Iran 15-Year Perspective for Anthrax Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 253: Iran 15-Year Perspective for Anthrax Treatment by Infection Type - Percentage Breakdown of Value Sales for Cutaneous Infection and Other Infection Types for the Years 2015, 2025 & 2030
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 256: Iran 15-Year Perspective for Anthrax Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 257: Israel Recent Past, Current & Future Analysis for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Israel Historic Review for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 259: Israel 15-Year Perspective for Anthrax Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 262: Israel 15-Year Perspective for Anthrax Treatment by Infection Type - Percentage Breakdown of Value Sales for Cutaneous Infection and Other Infection Types for the Years 2015, 2025 & 2030
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 265: Israel 15-Year Perspective for Anthrax Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Saudi Arabia Historic Review for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 268: Saudi Arabia 15-Year Perspective for Anthrax Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 15-Year Perspective for Anthrax Treatment by Infection Type - Percentage Breakdown of Value Sales for Cutaneous Infection and Other Infection Types for the Years 2015, 2025 & 2030
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 15-Year Perspective for Anthrax Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 275: UAE Recent Past, Current & Future Analysis for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: UAE Historic Review for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 277: UAE 15-Year Perspective for Anthrax Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 280: UAE 15-Year Perspective for Anthrax Treatment by Infection Type - Percentage Breakdown of Value Sales for Cutaneous Infection and Other Infection Types for the Years 2015, 2025 & 2030
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 283: UAE 15-Year Perspective for Anthrax Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Rest of Middle East Historic Review for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 286: Rest of Middle East 15-Year Perspective for Anthrax Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 15-Year Perspective for Anthrax Treatment by Infection Type - Percentage Breakdown of Value Sales for Cutaneous Infection and Other Infection Types for the Years 2015, 2025 & 2030
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 15-Year Perspective for Anthrax Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • AFRICA
    • Anthrax Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 293: Africa Recent Past, Current & Future Analysis for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Africa Historic Review for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 295: Africa 15-Year Perspective for Anthrax Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 298: Africa 15-Year Perspective for Anthrax Treatment by Infection Type - Percentage Breakdown of Value Sales for Cutaneous Infection and Other Infection Types for the Years 2015, 2025 & 2030
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 301: Africa 15-Year Perspective for Anthrax Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제